Sjögren's syndrome: Where do we stand, and where shall we go?

Maldini, 2013, Epidemiology of primary Sjogren's syndrome in a French multi-racial/ethnic area, Arthritis Care Res Hob Lessard, 2013, Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome, Nat Genet, 45, 1284, 10.1038/ng.2792 Cruz-Tapias, 2012, HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies, Autoimmun Rev, 11, 281, 10.1016/j.autrev.2011.10.002 Tobon, 2012, Are autoimmune diseases predictable?, Autoimmun Rev, 11, 259, 10.1016/j.autrev.2011.10.004 Selmi, 2012, Heritability versus the role of the environment in autoimmunity, J Autoimmun, 39, 249, 10.1016/j.jaut.2012.07.011 Le Dantec, 2012, Epigenetics and Sjogren's syndrome, Curr Pharm Biotechnol, 13, 2046, 10.2174/138920112802273326 Thabet, 2013, Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells, J Autoimmun, 41, 175, 10.1016/j.jaut.2013.02.002 Altorok, 2013, Genome-wide DNA methylation patterns in naive CD4 T cells from patients with primary Sjogren's syndrome, Arthritis Rheum Kapsogeorgou, 2011, Cellular microRNAs (miRNAs) and Sjogren's syndrome: candidate regulators of autoimmune response and autoantigen expression, J Autoimmun, 37, 129, 10.1016/j.jaut.2011.05.003 Alevizos, 2011, MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome, Arthritis Rheum, 63, 535, 10.1002/art.30131 Singh, 2012, The T cell in Sjogren's syndrome: force majeure, not spectateur, J Autoimmun, 39, 229, 10.1016/j.jaut.2012.05.019 Cornec, 2012, B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment, J Autoimmun, 39, 161, 10.1016/j.jaut.2012.05.014 Berthelot, 2013, Regulatory B cells play a key role in immune system balance, Jt Bone Spine, 80, 18, 10.1016/j.jbspin.2012.04.010 Furuzawa-Carballeda, 2013, Peripheral regulatory cells immunophenotyping in primary Sjogren's syndrome: a cross-sectional study, Arthritis Res Ther, 15, R68, 10.1186/ar4245 Yao, 2013, Type I interferons in Sjogren's syndrome, Autoimmun Rev, 12, 558, 10.1016/j.autrev.2012.10.006 Brkic, 2013, Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression, Ann Rheum Dis, 72, 728, 10.1136/annrheumdis-2012-201381 Gottenberg, 2006, Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome, Proc Natl Acad Sci U S A, 103, 2770, 10.1073/pnas.0510837103 Rusakiewicz, 2013, NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome, Sci Transl Med, 5, 195, 10.1126/scitranslmed.3005727 Gliozzi, 2013, A link between interferon and augmented plasmin generation in exocrine gland damage in Sjogren's syndrome, J Autoimmun, 40, 122, 10.1016/j.jaut.2012.09.003 Bournia, 2012, Subgroups of Sjogren syndrome patients according to serological profiles, J Autoimmun, 39, 15, 10.1016/j.jaut.2012.03.001 Vitali, 2002, Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Ann Rheum Dis, 61, 554, 10.1136/ard.61.6.554 Jonsson, 2013, Autoantibodies present before symptom onset in primary Sjogren syndrome, J Am Med Assoc, 310, 1854, 10.1001/jama.2013.278448 Shiboski, 2012, American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort, Arthritis Care Res Hob, 64, 475, 10.1002/acr.21591 Cornec, 2014, Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjogren's syndrome, Arthritis Res Ther, 16, R15, 10.1186/ar4442 Sumida, 2014, The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjogren's syndrome: a critical review, J Autoimmun, 51, 44, 10.1016/j.jaut.2013.12.012 Pertovaara, 2011, Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren's syndrome, Rheumatol Oxf, 50, 1453, 10.1093/rheumatology/ker118 Binard, 2009, Is the blood B-cell subset profile diagnostic for Sjogren syndrome?, Ann Rheum Dis, 68, 1447, 10.1136/ard.2008.096172 De Vita, 1992, Salivary gland echography in primary and secondary Sjogren's syndrome, Clin Exp Rheumatol, 10, 351 Vitali, 2013, Is it the time to adopt salivary gland ultrasonography as an alternative diagnostic tool for the classification of patients with Sjogren's syndrome? Comment on the article by Cornec et al., Arthritis Rheum, 65, 1950, 10.1002/art.37945 Cornec, 2013, Contribution of salivary gland ultrasonography to the diagnosis of Sjogren's syndrome: toward new diagnostic criteria?, Arthritis Rheum, 65, 216, 10.1002/art.37698 Bootsma, 2013, Toward new classification criteria for Sjogren's syndrome?, Arthritis Rheum, 65, 21, 10.1002/art.37701 Cornec, 2013, Reply: to PMID 23108632, Arthritis Rheum, 65, 1951, 10.1002/art.37944 Duquenne, 2013, Current diagnostic tools for Sjögren's syndrome, Int J Clin Rheumatol, 8, 281, 10.2217/ijr.13.4 Rasmussen, 2014, Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort, Ann Rheum Dis, 73, 31, 10.1136/annrheumdis-2013-203845 van Bijsterveld, 1969, Diagnostic tests in the Sicca syndrome, Arch Ophthalmol, 82, 10, 10.1001/archopht.1969.00990020012003 Whitcher, 2010, A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry, Am J Ophthalmol, 149, 405, 10.1016/j.ajo.2009.09.013 Aletaha, 2010, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative, Ann Rheum Dis, 69, 1580, 10.1136/ard.2010.138461 Petri, 2012, Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum, 64, 2677, 10.1002/art.34473 Troyanov, 2005, Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients, Med Baltim, 84, 231, 10.1097/01.md.0000173991.74008.b0 van den Hoogen, 2013, 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative, Ann Rheum Dis, 72, 1747, 10.1136/annrheumdis-2013-204424 Radner, 2014, Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review, Ann Rheum Dis, 73, 114, 10.1136/annrheumdis-2013-203284 van der Helm-van Mil, 2012, The 2010 ACR/EULAR criteria for rheumatoid arthritis: do they affect the classification or diagnosis of rheumatoid arthritis?, Ann Rheum Dis, 71, 1596, 10.1136/annrheumdis-2012-201426 Baldini, 2012, Classification criteria for Sjogren's syndrome: a critical review, J Autoimmun, 39, 9, 10.1016/j.jaut.2011.12.006 Malladi, 2012, Primary Sjogren's syndrome as a systemic disease: a study of participants enrolled in an international Sjogren's syndrome registry, Arthritis Care Res Hob, 64, 911, 10.1002/acr.21610 Vitali, 2013, Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue, Ann Rheum Dis, 72, 476, 10.1136/annrheumdis-2012-202565 Bowman, 2014, Classification criteria for Sjogren's syndrome: nothing ever stands still!, Ann Rheum Dis, 73, 1, 10.1136/annrheumdis-2013-203953 Quartuccio, 2014, The classification criteria for Sjogren syndrome: issues for their improvement from the study of a large Italian cohort of patients, Ann Rheum Dis, 10.1136/annrheumdis-2013-205076 Baldini, 2013, Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients, Rheumatol Oxf Liang, 2013, Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis, Ann Rheum Dis Quartuccio, 2014, Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study, J Autoimmun, 51, 75, 10.1016/j.jaut.2013.10.002 Nocturne, 2013, Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome, Blood, 122, 4068, 10.1182/blood-2013-05-503383 Nezos, 2014, B-Cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome, J Autoimmun, 51, 89, 10.1016/j.jaut.2013.04.005 Tobon, 2010, The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome, Arthritis Rheum, 62, 3447, 10.1002/art.27611 Tobon, 2013, Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome, Arthritis Rheum, 65, 3218, 10.1002/art.38129 Ramos-Casals, 2010, Treatment of primary Sjogren syndrome: a systematic review, J Am Med Assoc, 304, 452, 10.1001/jama.2010.1014 Seror, 2011, EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome, Ann Rheum Dis, 70, 968, 10.1136/ard.2010.143743 Seror, 2010, EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome, Ann Rheum Dis, 69, 1103, 10.1136/ard.2009.110619 Seror, 2012, Outcome measures for primary Sjogren's syndrome, J Autoimmun, 39, 97, 10.1016/j.jaut.2012.01.013 Seror, 2014, Outcome measures for primary Sjogren's syndrome: a comprehensive review, J Autoimmun, 51, 51, 10.1016/j.jaut.2013.12.010 Seror, 2013, European League Against Rheumatism Sjogren's Syndrome Disease Activity Index and European League Against Rheumatism Sjogren's Syndrome Patient-Reported Index: a complete picture of primary Sjogren's syndrome patients, Arthritis Care Res Hob, 65, 1358, 10.1002/acr.21991 Seror, 2014, Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI), Ann Rheum Dis, 10.1136/annrheumdis-2014-206008 Moerman, 2014, EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial, Ann Rheum Dis, 73, 472, 10.1136/annrheumdis-2013-203736 Cornec, 2013, The future of B cell-targeted therapies in Sjogren's syndrome, Immunotherapy, 5, 639, 10.2217/imt.13.49 Gottenberg, 2005, Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases, Ann Rheum Dis, 64, 913, 10.1136/ard.2004.029694 Pijpe, 2005, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study, Arthritis Rheum, 52, 2740, 10.1002/art.21260 Seror, 2007, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome, Ann Rheum Dis, 66, 351, 10.1136/ard.2006.057919 Devauchelle-Pensec, 2007, Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20), Arthritis Rheum, 57, 310, 10.1002/art.22536 Gottenberg, 2013, Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry, Ann Rheum Dis, 72, 1026, 10.1136/annrheumdis-2012-202293 St Clair, 2013, Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis, Arthritis Rheum, 65, 1097, 10.1002/art.37850 Carubbi, 2013, Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study, Arthritis Res Ther, 15, R172, 10.1186/ar4359 Dass, 2008, Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study, Ann Rheum Dis, 67, 1541, 10.1136/ard.2007.083865 Meijer, 2010, Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 62, 960, 10.1002/art.27314 Brown, 2014, The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy in patients with primary Sjogren's syndrome, BMC Musculoskelet Disord, 15, 21, 10.1186/1471-2474-15-21 Steinfeld, 2006, Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study, Arthritis Res Ther, 8, R129, 10.1186/ar2018 Mariette, 2013, Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis Maxwell, 2009, Abatacept for rheumatoid arthritis, Cochrane Database Syst Rev, 10.1002/14651858.CD007277.pub2 Adler, 2013, Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study, Arthritis Care Res Hob, 10.1002/acr.22052 Makino, 2013, Immune therapeutic potential of stem cells from human supernumerary teeth, J Dent Res, 92, 609, 10.1177/0022034513490732 Forbes, 2014, A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy, Clin Gastroenterol Hepatol, 12, 64, 10.1016/j.cgh.2013.06.021 Keyszer, 2011, Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases, Arthritis Rheum, 63, 2540, 10.1002/art.30431 Wang, 2013, Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience, Cell Transplant, 22, 2267, 10.3727/096368911X582769c Xu, 2012, Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome, Blood, 120, 3142, 10.1182/blood-2011-11-391144